Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651976 · ClinicalTrials.gov registry record · Early Phase 1
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
A Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 213
- Enrollment target
NCT00651976 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 213 participants.
The verdict
NCT00651976, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 213 participants
- Enrollment target
Study Summary
RATIONALE: Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving letrozole before surgery allows us to monitor the effects of letrozole on the tumor on a molecular level and determine markers of response to treatment. PURPOSE: This study will show us how well letrozole works in treating postmenopausal women with stage I, II or III breast cancer that can be removed by surgery.
Interventions
- OTHER Blood Collection
- DRUG letrozole
- PROCEDURE biopsy/lumpectomy/mastectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2008-03 |
| Est. Completion | 2018-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00651976
The ClinicalTrials.gov registry entry for NCT00651976 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Blood Collection is the first listed.
NCT00651976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00651976 about?
NCT00651976 is a clinical study titled "Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery". RATIONALE: Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving letrozole before surgery allows us to monitor the effects of letrozole on the tumor on a molecular level and determine markers of response to treatment. PURPOSE: This study w...
What is the current status of trial NCT00651976?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 213 participants. The study started on 2008-03. Estimated completion is 2018-09.
What interventions are being tested in trial NCT00651976?
The interventions under investigation include: Blood Collection (OTHER), letrozole (DRUG), biopsy/lumpectomy/mastectomy (PROCEDURE).
Who is sponsoring clinical trial NCT00651976?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.